Erika Dick, APRN
Primary Care · Chanute, KSNPI 1245685403
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.6% of the total across 121 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 18.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $759, 3.2 times the $239 reported in 2021.
Across 121 payments — averaging $16.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$371
- AstraZeneca$315
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$252
- Amgen$157
- AbbVie$140
- GSK$129
- plus $685 from 16 others
What the payments were for
- Food & beverage$2,02199%
- Education$281%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 23 | $371 |
| AstraZeneca | 16 | $315 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 16 | $252 |
| Amgen | 10 | $157 |
| AbbVie | 8 | $140 |
| GSK | 8 | $129 |
| Lilly USA, LLC | 8 | $110 |
| Johnson & Johnson | 4 | $70 |
| Pfizer | 4 | $68 |
| Sanofi | 3 | $62 |
| Lundbeck LLC | 3 | $56 |
| Shield Therapeutics Inc | 1 | $49 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $46 |
| Eisai Inc. | 2 | $37 |
| Dexcom, Inc. | 2 | $33 |
| Bayer | 2 | $29 |
| Otsuka America Pharmaceutical, Inc. | 2 | $29 |
| Novartis | 2 | $28 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $23 |
| Nestle Healthcare Nutrition Inc. | 1 | $17 |
| Seqirus USA Inc | 1 | $16 |
| Xeris Pharmaceuticals, Inc. | 1 | $14 |
How this compares
$2,049 in reported general payments places this provider in the 85th percentile of 56 primary care providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 41 | $49,786 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 60 | $42,518 |
| EliquisApixaban | 59 | $34,449 |
| LinzessLinaclotide | 44 | $28,050 |
| EntrestoSacubitril/Valsartan | 52 | $26,851 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 33 | $24,297 |
| XareltoRivaroxaban | 44 | $23,342 |
| Lurasidone Hcl | 21 | $19,570 |
| MovantikNaloxegol Oxalate | 44 | $19,181 |
| TrulicityDulaglutide | 15 | $16,803 |
| JardianceEmpagliflozin | 21 | $16,208 |
| JanuviaSitagliptin Phosphate | 29 | $13,665 |
| MyrbetriqMirabegron | 17 | $8,069 |
| Tresiba Flextouch U-200Insulin Degludec | 15 | $7,981 |
| Tresiba Flextouch U-100Insulin Degludec | 15 | $6,184 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $371 | $49,78641 claims |
| AstraZenecaBreztri Aerosphere | $315 | $42,51860 claims |
| PfizerEliquis | $68 | $34,44959 claims |
| AbbVieLinzess, Synthroid | $140 | $29,68968 claims |
| NovartisEntresto | $28 | $26,85152 claims |
| GSKTrelegy Ellipta | $129 | $24,29733 claims |
| Johnson & JohnsonXarelto | $70 | $23,34244 claims |
| Lilly USA, LLCTrulicity | $110 | $16,80315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 56 primary care providers in Kansas.
Other primary care in Chanute
- Michelle PragerTopeka$39K
- Kerry SanderStilwell$9K
- Kristina GroveOverland Park$9K
- Amy BakerLawrence$7K
- Thuy NguyenJetmore$4K
- Debra LyneSalina$4K
- Phuong DuongWichita$3K
- Danielle CarmitchelOverland Park$2K
- Jennifer ErkerGoddard$2K
- Mayra BrooksConcordia$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.